Modeling Sitagliptin Effect on Dipeptidyl Peptidase 4 (DPP4) Activity in Adults with Hematological Malignancies After Umbilical Cord Blood (UCB) Hematopoietic Cell Transplant (HCT)

BACKGROUND AND OBJECTIVES: Dipeptidyl peptidase-4 (DPP4) inhibition is a potential strategy to increase the engraftment rate of hematopoietic stem/progenitor cells. A recent clinical trial using sitagliptin, a DPP4 inhibitor approved for type 2 diabetes mellitus, has shown to be a promising approach...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: de Mendizábal, Nieves Vélez, Strother, Robert M., Farag, Sherif S., Broxmeyer, Hal E., Messina-Graham, Steven, Chitnis, Shripad D., Bies, Robert R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4133124/
https://ncbi.nlm.nih.gov/pubmed/24142388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-013-0109-y
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak